
REPL Stock Forecast & Price Target
REPL Analyst Ratings
Bulls say
Replimune Group Inc has significantly raised its probability of approval for its product candidate RP1 in combination with Opdivo for advanced melanoma patients, from 75% to 95%, based on promising clinical trial results showing an objective response rate of approximately 33.6%. The company's focus on in-house manufacturing is expected to provide cost advantages, contributing to favorable gross margins as it prepares for a global supply scale. Additionally, the advancement and global enrollment strategy for the IGNYTE-3 confirmatory trial position Replimune favorably for potential commercial launch by the end of the year, reinforcing the positive outlook for its stock.
Bears say
Replimune Group Inc. is projected to incur a net loss of $2.99 per share for fiscal 2025, indicative of persistent financial challenges. The company faces multiple risks, including potential failure to generate compelling data for its lead candidate RP1, setbacks in pivotal trials, and overall regulatory approval hurdles, all of which could severely impact its growth trajectory. Additionally, the possibility of medium- to long-term dilution risks further compounds the negative outlook surrounding the company's stock, particularly if development is halted due to safety concerns or lack of efficacy.
This aggregate rating is based on analysts' research of Replimune Group Inc and is not a guaranteed prediction by Public.com or investment advice.
REPL Analyst Forecast & Price Prediction
Start investing in REPL
Order type
Buy in
Order amount
Est. shares
0 shares